Open an account

Tillys

TLYS · NYSE

$4.63+$0.00 (+0.00%)TodayMarket closed ·
Prev close $4.63

About TLYS

Tilly's, Inc. engages in the retail of casual apparel, footwear, and accessories. The company is headquartered in Irvine, California and currently employs 1,314 full-time employees. The company went IPO on 2012-05-04. The Company’s stores are located in a variety of retail centers, including malls, lifestyle centers, power centers, community centers, outlet centers, and street-front locations. Customers may also shop online, where it features the same assortment of products as is carried in its stores, supplemented by additional online-only styles. The firm operates over 240 stores in 33 states. The firm's third-party brands include adidas, Affliction, Asics, BDG, Billabong, Birkenstock, Brixton, Converse, CVLA, Crocs, Dickies, Dr. Martens, Ed Hardy, edikted, Ethika, Free People, Herschel Supply Co., HHUF, Jansport, Katin, and others. The company supplements its third-party merchandise assortment with its own proprietary brands across many of its product categories. The company sells merchandise over the Internet through its e-commerce Website, www.tillys.com.

Employees
3,219
Headquarters
Irvine, California
Listed
May 4, 2012
Sector
Consumer Discretionary
Industry
Specialty Retail
Website
tillys.com

TLYS key statistics

Market cap
141.62M
Price-earnings ratio
77.17
Dividend yield
—
Average volume
218.91K
Volume
96.32K
Open price
$4.65
High today
$4.72
Low today
$4.60
52 Week high
$6.25
52 Week low
$1.14

Tillys (TLYS) at a glance

As of Oct 20, 2026, Tillys (TLYS) shares are priced at $4.63, giving the company a market cap of 141.62M and a price-to-earnings ratio of 77.17.

Today the stock has traded between $4.60 and $4.72. The current price is 0.7% above the day's low and 1.8% below its high.

Volume so far is 96.32K shares, below the average of 218.91K shares a day.

Over the past year Tillys has ranged from $1.14 to $6.25, and now sits 68% of the way up that range.

Tillys met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY27 it reported $0.27 per share against an estimate of $0.1734.

TLYS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 134.5% on average.

  1. Q3 FY25: reported -$0.428 per share against an estimate of -$0.3774
  2. Q4 FY25: reported -$0.45 per share against an estimate of -$0.3009
  3. Q1 FY26: reported -$0.74 per share against an estimate of -$0.6732
  4. Q2 FY26: reported $0.10 per share against an estimate of -$0.0408
  5. Q3 FY26: reported -$0.05 per share against an estimate of -$0.306
  6. Q4 FY26: reported $0.10 per share against an estimate of -$0.153
  7. Q1 FY27: reported -$0.26 per share against an estimate of -$0.3366
  8. Q2 FY27: reported $0.27 per share against an estimate of $0.1734

TLYS news

  • Avi Kapoor

    Gold Jumps 3%; ISM Services PMI Rises In August

  • Avi Kapoor

    Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher

  • 12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

  • Tanya Rawat

    Tillys (TLYS) Shares Jump 36% After Hours: Here's Why

  • 12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

  • Press releaseBusiness Wire

    Tilly’s, Inc. to Report Fiscal 2026 Second Quarter Operating Results on September 2, 2026

  • 12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

  • 12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

Similar companies

Companies in the same industry as Tillys

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.